Download PDF
Thromb Haemost 1993; 70(04): 608-616
DOI: 10.1055/s-0038-1649637
Original Article
Coagulation
Schattauer GmbH Stuttgart

A Quantitative Thrombin Time for Determining Levels of Hirudin and Hirulog™

Thomas J Reid III
The Department of Hematology, Walter Reed Army Institute of Research, Washington, DC, USA
,
Barbara M Alving
The Department of Hematology, Walter Reed Army Institute of Research, Washington, DC, USA
› Author Affiliations
Further Information

Publication History

Received 09 February 1993

Accepted after revision 19 May 1993

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The anticoagulant effect of recombinant hirudin (rHir) and HirulogTM has been monitored in patients with the activated partial thromboplastin time. Accurate monitoring with this test cannot be achieved if plasmas contain heparin, lupus anticoagulants, low concentrations of fibrinogen or other factors, or elevated fibrinogen-fibrin degradation products (FDP). We have therefore developed a simple, rapid, sensitive clot-based method, the quantitative thrombin time (QTT), to measure levels of rHir and HirulogTM in patient plasma (or whole blood). The QTT is performed by mixing a 1:10 dilution of patient plasma (50 μl) with human fibrinogen (50 μl, 128 mg/dl) at 37° C; the clotting time is initiated by adding human thrombin (50 μl, 5-7.5 U/ml). The concentration of HirulogTM or rHir in plasma can be determined by comparing the QTT in patient plasma with a Standard curve that is generated by adding different concentrations of anticoagulant to pooled normal plasma. Studies with whole blood using the same procedure yield similar results. In the absence of HirulogTM or rHir, the baseline QTT is the same in normal and abnormal plasmas (fibrinogen <150 mg/dl and FDP as high as 1024 μg/ml, elevated FDP alone, lupus anticoagulant, or heparin <0.9 U/ml). When known concentrations of either rHir or HirulogTM are added to abnormal plasmas, the mean observed concentrations as determined by the QTT deviate from the expected values by less than 10% (range 0-19%). The data indicate that the QTT is a simple, rapid, and accurate test for the determination of levels of rHir and HirulogTM in plasma or whole blood.

 

  • References

  • 1 Markwardt F, Hauptman J, Nowak G, Kleßen CH, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemostas 1982; 47: 226-229
    PubMedGoogle Scholar
  • 2 Kaiser B, Markwardt F. Antithrombotic and hemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613-620
    CrossrefPubMedGoogle Scholar
  • 3 Bucha E, Nowak G, Markwardt F. Prevention of experimental coronary thrombosis by hirudin. Folia Haematol 1988; 115: 52-58
    PubMedGoogle Scholar
  • 4 Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res 1989; 54: 435-445
    CrossrefPubMedGoogle Scholar
  • 5 Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 1989; 61: 77-80
    PubMedGoogle Scholar
  • 6 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989; 79: 657-665
    CrossrefPubMedGoogle Scholar
  • 7 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
    CrossrefPubMedGoogle Scholar
  • 8 Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury in the pig. Circulation 1990; 82: 1476-1484
    CrossrefPubMedGoogle Scholar
  • 9 Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemostas 1990; 63: 44-47
    PubMedGoogle Scholar
  • 10 Freund M, Cazenave J-P, Courtney M, Degryse E, Roitsch C, Bernat A, Delebassée D, Defreyn G, Maffrand J-P. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemostas 1990; 63: 187-192
    PubMedGoogle Scholar
  • 11 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
    CrossrefPubMedGoogle Scholar
  • 12 Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243
    CrossrefPubMedGoogle Scholar
  • 13 Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. The characterization of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effective of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemostas 1991; 65: 268-274
    PubMedGoogle Scholar
  • 14 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombosis formation in baboons. Blood 1991; 77: 1006-1012
    PubMedGoogle Scholar
  • 15 Gray E, Watton J, Cesmeli S, Barrowcliffe TW, Thomas DP. Experimental studies on a recombinant hirudin, CGP 39393. Thromb Haemostas 1991; 65: 355-359
    PubMedGoogle Scholar
  • 16 Cadroy Y, Maraganore JM, Hanson SR, Harker LA. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent throm-bosis in baboons. Proc Natl Acad Sci USA 1991; 88: 1177-1181
    CrossrefPubMedGoogle Scholar
  • 17 Broersma RJ, Kutcher LW, Heminger EF, Krstenansky JL, Marshall FN. Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals. Thromb Haemostas 1991; 65: 377-381
    PubMedGoogle Scholar
  • 18 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent in medicinal leeches. Biomed Biochim Acta 1985; 44: 1007-1013
    PubMedGoogle Scholar
  • 19 Markwardt F, Nowak G, Sturzebecher J, Vogel G. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393-400
    CrossrefPubMedGoogle Scholar
  • 20 Minar E, Zazgornik J. Local hirudin application – an aid in preventing occlusion of an arteriovenous fistula in dialysis patients?. Klin Wschr 1985; 63: 190-191
    CrossrefPubMedGoogle Scholar
  • 21 Vogel G, Markwardt F. Clinical use of hirudin. Folia Haematol 1988; 115: 113
    PubMedGoogle Scholar
  • 22 Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of HirulogTM, a direct thrombin inhibitor, in humans. Thromb Haemostas 1993; 69: 157
    PubMedGoogle Scholar
  • 23 Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemostas 1989; 15: 269-282
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Berscheid G, Grötsch H, Neubauer H, Pünter J, Reindl J, Seipp P. Determination of R DNA hirudin and alpha-human thrombin-hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex vs chromogenic thrombin substrate assay. Thromb Res 1992; 66: 33-42
    CrossrefPubMedGoogle Scholar
  • 25 Bichler J, Siebeck M, Fichtl B, Fritz H. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. Haemostasis 1991; 21: 137-141
    PubMedGoogle Scholar
  • 26 Bichler J, Siebeck R, Maschler R, Pelzer H, Fritz H. Determination of thrombin-hirudin complex in plasma with an enzyme-linked immunosorbent assay. Blood Coagul Fibrinol 1991; 2: 129-133
    CrossrefPubMedGoogle Scholar
  • 27 Grießbach U, Sturzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-350
    CrossrefPubMedGoogle Scholar
  • 28 Spannagl M, Bichler H, Lill H, Schramm W. A fast photometric assay for the determination of hirudin. Haemostasis 1991; 21 (Suppl. 01) 36-40
    PubMedGoogle Scholar
  • 29 Walenga JM, Hoppensteadt D, Koza M, Wallock M, Pifarre R, Fareed J. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis 1991; 21: 49-63
    PubMedGoogle Scholar
  • 30 Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagul Fibrinol 1991; 2: 121-127
    CrossrefPubMedGoogle Scholar
  • 31 Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-Hirudin. Semin Thromb Hemostas 1991; 17: 103-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Riehl-Bellon N, Carvallo D, Acker M, van Dorsselaer A, Marquet M, Loison G, Lemoine Y, Brown SW, Courtney M, Roitsch C. Purification and characterization of recombinant hirudin produced by Saccharomyces cerevisiae. Biochemistry 1989; 28: 2941-2949
    CrossrefPubMedGoogle Scholar
  • 33 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a new class of divalent peptide inhibitors of thrombin. J Biol Chem 1990; 29: 7095-7101
    PubMedGoogle Scholar
  • 34 Alving BM, Barr CB, Johansen LE, Tang DB. Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper venom time for verification of lupus anticoagulants. Thromb Haemostas 1992; 67: 672-678
    PubMedGoogle Scholar
  • 35 Abdilgaard U, Lie M, Ødegãrd OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and chromozym TH). Thromb Res 1977; 11: 549-552
    CrossrefPubMedGoogle Scholar
  • 36 Linker A, Hovingh P. Heparinase and heparitinase from Flavobacteria. Meth Enzymol 1972; 28: 902-911
    PubMedGoogle Scholar
  • 37 Stone SR, Dennis S, Hofsteenge J. Quantitative evaluation of the contribution of ionic interactions to the formation of the thrombin-hirudin complex. Biochemistry 1989; 28: 6857-63
    CrossrefPubMedGoogle Scholar
  • 38 Markwardt F, Sturzebecher J, Walsmann P. The hirudin standard. Thromb Res 1990; 59: 395-400
    CrossrefPubMedGoogle Scholar
  • 39 Sturzebecher J. Methods for determination of hirudin. Semin Thromb Hemostas 1991; 17: 99-102
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Krstenansky JL, Broersma RJ, Owen TJ, Payne MH, Yates MT, Mao SJT. Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin. Thromb Haemostas 1990; 63: 208-214
    PubMedGoogle Scholar
  • 41 Ginsberg JS, Hirsh J, Gent M, KcKinnon B, Turpie AGG, Levine M, Powers P, Weitz J, Findlen K, Neemeh J, Buller H, Adelman B, Maraganore J, Fox I. A Phase II study of hirulog in the prevention of venous thrombosis after major hip and knee surgery. Circulation 1992; 86 (Suppl. 01) 409
    PubMedGoogle Scholar
  • 42 Dreyfus M, Bridey F, Brosse A, Fischer AM, Parent F, Grötsch H, Simmonneau G, Meyer D. Recombinant hirudin (HBW 023): Treatment of 10 patients with severe thromboembolism; biological data. Blood 1992; 80 (Suppl. 01) 320a
    PubMedGoogle Scholar
  • 43 Lidón R-M, Adelman B, Maraganore J, Théroux P. Hirulog, a direct thrombin inhibitor, for the management of unstable angina. Circula-tion 1992; 86 (Suppl. 01) 386
    PubMedGoogle Scholar
  • 44 Sharma GVRK, Lapsley DE, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Safety and efficacy of hirulog in patients with unstable angina. Circulation 1992; 86 (Suppl. 01) 386
    PubMedGoogle Scholar
  • 45 van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Rijnierse J, Serruys PW, Suryapranata H, Zijlstra F. Ptca with hirudin associated with less acute cardiac complications than heparin. Circulation 1992; 86 (Suppl. 01) 372
    PubMedGoogle Scholar
  • 46 Weitz JI, Hudoba N, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is not susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedGoogle Scholar